THRB and metabolic dysfunction-associated steatohepatitis: Resmetirom, a liver-targeted THR-β selective agonist, showing promising results in the improvement of hepatic fibrosis and MASH resolution, has recently received FDA approval for non-cirrhotic MASH patients with moderate to advanced fibrosis, along with dietary and exercise interventions [104].